Dominant truncating variants in KAT6A cause two neurodevelopmental disorders with opposite gene regulatory and metabolic changes

Verdict. Here, we reveal that this clinical stratification reflects fundamentally distinct molecular mechanisms driven by variant position in the gene. It intersects mitochondrial stress/dysfunction themes (disease context; systemic metabolic stress).

What the authors report

Arboleda-Tham Syndrome (ARTHS), caused by truncating variants in KAT6A, is currently diagnosed as a single neurodevelopmental syndrome with variable severity of intellectual disability and multi-system findings. This mechanistic distinction enables precision therapeutics: late-truncating variants are amenable to KAT6A inhibition, while early-truncating variants require loss-of-function rescue.

Key results stated in the abstract include the following. Here, we reveal that this clinical stratification reflects fundamentally distinct molecular mechanisms driven by variant position in the gene. Using patient-derived iPSCs and multi-omics profiling, we demonstrate that early-truncating variants (exons 1-15) cause loss-of-function via nonsense-mediated decay (NMD), while late-truncating variants (exons 16-17) that escape NMD cause gain-of-function effects. These opposite mechanisms are reflected in distinctive facial gestalt features and DNA-methylation episignatures and invert the direction of change across neuronal gene regulation, metabolism, and mitochondrial physiology.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to redox biology, metabolism, neurobiology, therapeutics. It is relevant to mitochondrial dysfunction discourse because the abstract invokes disease context, systemic metabolic stress. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Causal language appears in the abstract; such claims should be treated as provisional until design details (loss-of-function, rescue, dose-response) are verified. Server: medrxiv. Posted 2026-08-14. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

Using patient-derived iPSCs and multi-omics profiling, we demonstrate that early-truncating variants (exons 1-15) cause loss-of-function via nonsense-mediated decay (NMD), while late-truncating variants (exons 16-17) that escape NMD cause gain-of-function effects.

Principal findings

1. Here, we reveal that this clinical stratification reflects fundamentally distinct molecular mechanisms driven by variant position in the gene.
2. Using patient-derived iPSCs and multi-omics profiling, we demonstrate that early-truncating variants (exons 1-15) cause loss-of-function via nonsense-mediated decay (NMD), while late-truncating variants (exons 16-17) that escape NMD cause gain-of-function effects.
3. These opposite mechanisms are reflected in distinctive facial gestalt features and DNA-methylation episignatures and invert the direction of change across neuronal gene regulation, metabolism, and mitochondrial physiology.
4. Variant-level stratification is therefore essential: mechanistic understanding, not gene-level diagnosis alone, is prerequisite for developing rational therapeutic strategies in rare Mendelian disease.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Comparator/control language is weak or absent in the abstract, limiting causal inference from this brief alone.
• Primary source: medrxiv DOI 10.64898/2026.08.11.26358095 (posted 2026-08-14).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• Is the mitochondrial phenotype cell-autonomous in neurons/glia, or secondary to systemic/inflammatory signals?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on redox biology, metabolism, neurobiology, this preprint is worth full-text review if the topic matches your program. Abstract-level takeaway: Here, we reveal that this clinical stratification reflects fundamentally distinct molecular mechanisms driven by variant position in the gene. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.